首页> 美国卫生研究院文献>Case Reports in Oncology >Complex Chromosome-Positive Acute Myelogenous Leukemia Identified 16 Months following the Completion of Capecitabine Chemotherapy for Early-Stage Colon Cancer
【2h】

Complex Chromosome-Positive Acute Myelogenous Leukemia Identified 16 Months following the Completion of Capecitabine Chemotherapy for Early-Stage Colon Cancer

机译:复杂染色体阳性急性髓性白血病在氯硝滨化疗完成后在早期结肠癌完成后鉴定了16个月

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Capecitabine is an oral chemotherapy that is used to treat several cancer types, including breast, gastrointestinal, hepatobiliary, and ovarian. The use of antimetabolites in cancer therapy has generally not been associated with leukemogenesis. In this report, we demonstrate a case of capecitabine-related acute myeloid leukemia that was diagnosed 16 months after the completion of treatment for early-stage colon cancer, by a complex chromosome analysis 48,XY,6,del(7)(q22),+8,+13,t(13;17)(q12;p13),t(13,21)(q12;122),+mar [Gazi Med J. 2018 Jan;29(1):57–58]. This is the first report to our knowledge of the development of t-AML in a patient with early-stage colon cancer that was caused by capecitabine. We should use capecitabine with caution. Further studies are essential to investigate capecitabine-triggered leukemogenesis.
机译:Capecitabine是一种口服化疗,用于治疗几种癌症类型,包括乳腺癌,胃肠道,肝胆和卵巢癌。在癌症疗法中使用抗体代谢物通常没有与白血病有关。在本报告中,我们证明了一种核发萘相关急性髓性白血病,其在治疗早期结肠癌完成后诊断为16个月,通过复杂的染色体分析48,XY,6,Del(7)(Q22) ,+ 8,+ 13,t(13; 17)(q12; p13),t(13,21)(q12; 122),+ mar [Gazi Med J. 2018 Jan; 29(1):57-58] 。这是我们对患有早期结肠癌的患者的T-AML发育的第一个报告,该癌症是由Capecitabine引起的。我们应该谨慎使用capecitabine。进一步的研究对于调查Capecitabine触发的白血病至关重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号